The earnings call presented a mixed picture, with strong performance in spatial consumables and successful new product launches offset by declines in overall revenue and instrument sales. Ongoing macroeconomic challenges and funding uncertainties continue to pose challenges.

Company Guidance

During the third quarter of 2025, 10X Genomics exceeded the top end of its guidance range, achieving a total revenue of $149 million despite facing ongoing macroeconomic challenges. Spatial consumables experienced robust double-digit year-over-year revenue growth, driven by strong demand for Xenium consumables, which saw increased usage in both the number of runs and average spend per run. In contrast, single-cell consumable revenue declined year-over-year, although there was a double-digit growth in Chromium consumables reactions. The company ended the quarter with $482 million on the balance sheet, reflecting a commitment to cost management and cash generation. Looking forward, 10X Genomics anticipates fourth-quarter revenue in the range of $154 million to $158 million, with no significant change expected in customer purchasing behavior and ongoing cautious spending patterns, especially concerning capital expenditures.

Exceeded Revenue Guidance

10X Genomics reported total revenue of $149 million for the third quarter, exceeding the top end of their guidance range.

Strong Performance of Spatial Consumables

Spatial consumables revenue grew by 19% year-over-year, driven by strong demand for Xenium consumables.

Launch of Next-Generation Chromium Flex

10X Genomics began shipping the next generation of Chromium Flex, which offers improved sensitivity, robustness, scalability, and cost-effectiveness.

Partnership with Anthropic for Data Analysis

The partnership with Anthropic aims to address the data analysis bottleneck by integrating with Claude for Life Sciences, making data analysis more accessible.

Successful Balance Sheet Management

The company ended the quarter with $482 million in cash, cash equivalents, and marketable securities, up $35 million from the prior quarter.

10x Genomics (TXG) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TXG Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 18, 2026	2025 (Q4)	-0.22 / -	-0.4	―	―	―
Nov 06, 2025	2025 (Q3)	-0.29 / -0.22	-0.3	26.67% (+0.08)	―
Aug 07, 2025	2025 (Q2)	-0.37 / 0.28	-0.32	187.50% (+0.60)	―
May 08, 2025	2025 (Q1)	-0.47 / -0.28	-0.5	44.00% (+0.22)	―
Feb 12, 2025	2024 (Q4)	-0.30 / -0.40	-0.41	2.44% (<+0.01)	―
Oct 29, 2024	2024 (Q3)	-0.33 / -0.30	-0.79	62.03% (+0.49)
Aug 08, 2024	2024 (Q2)	-0.48 / -0.32	-0.53	39.62% (+0.21)	―
Apr 30, 2024	2024 (Q1)	-0.50 / -0.50	-0.44	-13.64% (-0.06)	―
Feb 15, 2024	2023 (Q4)	-0.35 / -0.41	-0.15	-173.33% (-0.26)	―
Nov 02, 2023	2023 (Q3)	-0.46 / -0.79	-0.37	-113.51% (-0.42)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TXG Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2025	$13.00	$15.25	+17.31%
Aug 07, 2025	$12.80	$12.29	-3.98%
May 08, 2025	$8.63	$8.77	+1.62%
Feb 12, 2025	$12.00	$11.94	-0.50%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does 10x Genomics Inc (TXG) report earnings?

10x Genomics Inc (TXG) is schdueled to report earning on Feb 18, 2026, After Close (Confirmed).

What is 10x Genomics Inc (TXG) earnings time?

10x Genomics Inc (TXG) earnings time is at Feb 18, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TXG EPS forecast?

TXG EPS forecast for the fiscal quarter 2025 (Q4) is -0.22.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing